Phosphodiesterase-4B-Inhibitor zur Behandlung der idiopathischen Lungenfibrose (IPF)

Hostettler K (2016) Idiopathische Lungenfibrose – Pathogenese und therapeutische Konzepte. Ther Umsch 73(1):19–24

Raghu G, Remy-Jarin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:e18–e47

Heng L, Jianping Z, Wei T (2018) Phosphodiesterase‑4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 9:1048

Schick MA, Schlegel N (2022) Clinical implication of Phosphodiesterase-4-inhibition. Int J Mol Sci 23(3):1209